Fig. S3.

PD98059 (PD) augments crizotinib-induced growth inhibition in multiple NSCLC cell lines by promoting apoptosis and G2/M arrest. (a) Cells were treated with crizotinib in the presence or absence of PD98059 for 48 h. Cell viability was measured by MTS assay. (b) Cells were treated with crizotinib in the presence or absence of PD98059 for 48 h, quantification of the apoptotic rates was analyzed by flow cytometry. (c) Cells were treated with crizotinib in the presence or absence of PD98059 for 24 h, quantification of the relative cell populations in each cell cycle stage was analyzed by flow cytometry. (d) Immunoblotting for the corresponding proteins in cells treated with crizotinib alone or in combination with PD98059 for 48 h. Values of (a) were presented as mean ± SD and compared using one-way ANOVA. Values of (b) and (c) were presented as mean ± SD and compared using student's t-test. *P < 0.05, **P < 0.01, and *** P < 0.001.